Patents by Inventor Zhenrong Xu
Zhenrong Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240118157Abstract: An ambient pressure compensation structure for an ultraviolet difference spectrum gas sensor includes a closed box, an ultraviolet difference spectrum gas sensor, a digital pressure sensor, a thermostatic controller, an industrial control computer, a pressure regulating assembly and a limiting partition; the pressure regulating assembly and the limiting partition are arranged inside the closed box, the pressure regulating assembly comprises a piston, a regulating rod and a driving motor, the left side of the piston is connected with the regulating rod, the front end of the regulating rod penetrates out of the closed box and is connected with the driving motor, and the piston divides the interior of the closed box into a pressure regulating air chamber and a working air chamber. Also disclosed is an ambient pressure compensation method for an ultraviolet difference spectrum gas sensor.Type: ApplicationFiled: December 19, 2023Publication date: April 11, 2024Inventors: Fuchao TIAN, Yuntao LIANG, Shuanglin SONG, Xing AI, Yazhou XU, Weiwei SU, Baolong GUO, Zhenrong LI
-
Publication number: 20230331725Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.Type: ApplicationFiled: June 16, 2023Publication date: October 19, 2023Inventors: Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
-
Patent number: 11780839Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.Type: GrantFiled: March 27, 2019Date of Patent: October 10, 2023Assignee: PTC THERAPEUTICS, INC.Inventors: Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
-
Publication number: 20230114728Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: ApplicationFiled: September 24, 2020Publication date: April 13, 2023Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Jodie HAMRICK, Steven A. BOYD, Allison L. ZULLI, Stephen M. CONDON, Cullen L. MYERS, Zhenrong XU, Tsuyoshi Uehara, Nathan LINE
-
Publication number: 20220251098Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.Type: ApplicationFiled: April 18, 2022Publication date: August 11, 2022Inventors: Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu
-
Patent number: 11407753Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.Type: GrantFiled: June 5, 2018Date of Patent: August 9, 2022Assignee: PTC THERAPEUTICS, INC.Inventors: Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu
-
Publication number: 20210198288Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: ApplicationFiled: May 23, 2019Publication date: July 1, 2021Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Jodie HAMRICK, Steven A. BOYD, Allison L. ZULLI, Eugen F. MESAROS, Stephen M. CONDON, Robert E. Lee TROUT, Cullen L. MYERS, Zhenrong XU
-
Patent number: 11008340Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: November 17, 2016Date of Patent: May 18, 2021Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Lanqi Jia, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Linghang Zhuang
-
Publication number: 20210024525Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.Type: ApplicationFiled: March 27, 2019Publication date: January 28, 2021Inventors: Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
-
Publication number: 20200165256Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.Type: ApplicationFiled: June 5, 2018Publication date: May 28, 2020Inventors: Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu
-
Patent number: 10654884Abstract: Provided are novel purine nucleoside/nucleotide analogues compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.Type: GrantFiled: April 23, 2015Date of Patent: May 19, 2020Assignee: Boehringer Ingelheim International GmbHInventors: Salvacion Cacatian, David A. Claremon, Lanqi Jia, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Yajun Zheng
-
Publication number: 20190322687Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: ApplicationFiled: November 17, 2016Publication date: October 24, 2019Applicant: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Lanqi Jia, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Linghang Zhuang
-
Patent number: 10336717Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.Type: GrantFiled: October 15, 2015Date of Patent: July 2, 2019Assignee: Vitae Pharmaceuticals, LLCInventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Klaus Fuchs, Niklas Heine, Lanqi Jia, Katerina Leftheris, Brian McKeever, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Guosheng Wu, Zhongren Wu, Zhenrong Xu, Jing Yuan, Yajun Zheng
-
Publication number: 20180344734Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.Type: ApplicationFiled: March 12, 2018Publication date: December 6, 2018Inventors: Yuri Bukhtiyarov, Salvacion Cacatian, Lawrence Wayne Dillard, Cornelia Dorner-Ciossek, Klaus Fuchs, Lanqi Jia, Deepak S. Lala, Angel Morales-Ramos, Jonathan Reeves, Suresch B. Singh, Shankar Venkatraman, Zhenrong Xu, Jing Yuan, Yi Zhao, Yajun Zheng, Georg Rast
-
Patent number: 9949975Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.Type: GrantFiled: December 19, 2016Date of Patent: April 24, 2018Assignee: Vitae Pharmaceuticals, Inc.Inventors: Yuri Bukhtiyarov, Salvacion Cacatian, Lawrence Wayne Dillard, Cornelia Dorner-Ciossek, Klaus Fuchs, Lanqi Jia, Deepak S. Lala, Angel Morales-Ramos, Jonathan Reeves, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Jing Yuan, Yi Zhao, Yajun Zheng, Georg Rast
-
Publication number: 20170196867Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.Type: ApplicationFiled: December 19, 2016Publication date: July 13, 2017Applicant: Vitae Pharmaceuticals, Inc.Inventors: Yuri Bukhtiyarov, Salvacion Cacatian, Lawrence Wayne Dillard, Cornelia Dorner-Ciossek, Klaus Fuchs, Lanqi Jia, Deepak S. Lala, Angel Morales-Ramos, Jonathan Reeves, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Jing Yuan, Yi Zhao, Yajun Zheng, Georg Rast
-
Publication number: 20170044203Abstract: Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.Type: ApplicationFiled: April 23, 2015Publication date: February 16, 2017Inventors: Salvacion Cacatian, David A. Claremon, Lanqi Jia, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Yajun Zheng
-
Patent number: 9526727Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.Type: GrantFiled: February 4, 2015Date of Patent: December 27, 2016Assignee: Vitae Pharmaceutical, Inc.Inventors: Yuri Bukhtiyarov, Salvacion Cacatian, Lawrence Wayne Dillard, Cornelia Dorner-Ciossek, Klaus Fuchs, Lanqi Jia, Deepak S. Lala, Angel Morales-Ramos, Jonathan Reeves, Suresh B. Singh, Shankar Venkatraman, Zhenrong Xu, Jing Yuan, Yi Zhao, Yajun Zheng, Georg Rast
-
Publication number: 20160272600Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.Type: ApplicationFiled: October 15, 2015Publication date: September 22, 2016Inventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Klaus Fuchs, Niklas Heine, Lanqi Jia, Katerina Leftheris, Brian McKeever, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Guosheng Wu, Zhongren Wu, Zhenrong Xu, Jing Yuan, Yajun Zheng
-
Patent number: 9212153Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.Type: GrantFiled: December 18, 2013Date of Patent: December 15, 2015Assignees: Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbHInventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Klaus Fuchs, Niklas Heine, Lanqi Jia, Katerina Leftheris, Brian McKeever, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Guosheng Wu, Zhongren Wu, Zhenrong Xu, Jing Yuan, Yajun Zheng